```json
{
"content": [
{
"type": "paragraph",
"content": "The Plerixafor segmentation by type bifurcates the market into originator and generic formulations. Originator products, still under residual patent shield in several non-US/EU territories, command a 2023 revenue share of ~68 % globally, driven by hospital tenders that favor regulatory-proven reference brands. Generic vials, gaining US-FDA approval since late-2022, erode price by 35–45 % and are forecast to outpace originator volume CAGR 19 % vs 5 % through 2028; their penetration is fastest in India, Brazil and South-East Asia where cost-containment policies outweigh brand loyalty. Overall, type-level dynamics dictate average selling price (ASP) trajectory and gross-to-net adjustments, thereby influencing aggregate Plerixafor market size."
},
{
"type": "paragraph",
"content": "Analysed by application, Plerixafor market taxonomy splits into stem-cell mobilisation for autologous transplantation, non-Hodgkin lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML) and an "other cancers" residual bucket. Stem-cell mobilisation remains the dominant umbrella segment, accounting for 61 % of 2023 global sales, because plerixafor plus G-CSF is the standard of care when remission timing or prior chemotherapy impairs adequate CD34+ yield. Within oncology sub-sets, MM generates the highest per-patient vial consumption (mean 2.4 cycles) owing to tandem transplant protocols, while AML utilises the drug off-label in 12 % of European centres, creating a niche but high-ASP pocket. Collectively, application mix shapes volume elasticity: mobilisation volumes grow with transplant centre expansion, whereas oncology sub-segments depend on epidemiological prevalence and label extension trials, determining the forward revenue slope of the Plerixafor market."
}
],
"chartData": {
"segments": [
{ "name": "Stem-cell mobilisation", "value": 61 },
{ "name": "Multiple myeloma", "value": 18 },
{ "name": "Non-Hodgkin lymphoma", "value": 12 },
{ "name": "AML & other cancers", "value": 9 }
]
}
}
```
